Illumina Inc (ILMN)

Nov 1, 2026

Illumina's stock (ILMN) dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year outlook. The decline was attributed to missing revenue estimates and the broader market selloff in AI stocks, although the healthcare sector generally rose that day. The article notes that while other peers also fell, Illumina's drop was significantly larger, suggesting company-specific factors were at play.

Oct 29, 2026

Illumina reported strong Q3 2026 financial results with $1.17 billion in revenue, up 4.7% year-over-year on a rest-of-world organic basis, driven by clinical sequencing demand and NovaSeq X placements. The company raised its full-year guidance, anticipating revenue between $4.64 billion and $4.66 billion, and highlighted strategic initiatives like the Billion Cell Atlas and BioInsight platform for future growth in AI-ready datasets and multi-omics. Management expressed confidence in achieving long-term financial targets, citing robust market conditions, particularly in the clinical sector, and ongoing innovation as key growth drivers.

Oct 29, 2026

Illumina Inc. (NASDAQ:ILMN) reported third-quarter results that surpassed analyst expectations for both adjusted EPS and revenue. Despite this earnings beat and a raised full-year guidance, the company's shares fell 12% in after-hours trading due to a decline in China revenue, which weighed heavily on investor sentiment. CEO Jacob Thaysen noted healthy clinical demand and strong NovaSeq X placements as key drivers for the positive results.

Oct 28, 2026

Illumina Inc. (ILMN) stock gained 3.33% on Wednesday, reaching $288.79, in a positive trading session where both the S&P 500 and Dow Jones Industrial Average also rose. Despite this daily gain and being its fourth consecutive day of increases, the stock underperformed when compared to some of its competitors.

Oct 28, 2026

Wall Street analysts predict Illumina (ILMN) will report Q3 earnings of $1.36 per share, a 1.5% increase year-over-year, with revenues forecasted at $1.14 billion, up 4.9%. The consensus EPS estimate has remained stable over the past 30 days. The article details specific revenue estimates for various segments like consumables, instruments, sequencing, and microarrays, indicating expected changes from the prior-year quarter.

Oct 27, 2026

Illumina Inc. (ILMN) stock rallied 3.11% to $279.47, outperforming the broader market on a strong trading day. The S&P 500 Index rose 0.60% and the Dow Jones Industrial Average rose 0.03%. This marks the third consecutive day of gains for Illumina's stock.